Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 5/20 | 0.52 |
| ▸ | APLNR | P35414 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.47 |
| ▸ | CALCR | P30988 | 3/20 | 0.47 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.46 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433176 | 0.99 | CAPN1 (0.52) | CAPN1APLNRPLK1OPRM1OPRK1 | |
| SCHEMBL31433171 | 0.91 | CAPN1 (0.49) | CAPN1APLNRPLK1OPRM1OPRK1 | |
| SCHEMBL29421085 | 0.88 | RAMP3 (0.49) | CAPN1APLNRPLK1OPRM1OPRK1 | |
| SCHEMBL29421104 | 0.88 | RAMP3 (0.49) | CAPN1APLNRPLK1OPRM1OPRK1 | |
| SCHEMBL31433268 | 0.87 | RAMP3 (0.55) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL31433260 | 0.86 | RAMP3 (0.55) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL31433204 | 0.85 | OPRM1 (0.49) | APLNROPRM1OPRK1RAMP3CALCR | |
| SCHEMBL29421084 | 0.83 | OPRM1 (0.52) | OPRM1OPRK1RAMP3CALCRNMUR2 | |
| SCHEMBL29611971 | 0.81 | CAPN1 (0.54) | CAPN1OPRM1OPRK1CTSBRAMP3 | |
| SCHEMBL28076148 | 0.81 | KEAP1 (0.48) | APLNROPRM1OPRK1RAMP3CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | CAPN1 3160/4885APLNR 2565/4885PLK1 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.